Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.39 |
| ▸ | HTR1A | P08908 | 8/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982940 | 0.84 | ADRA1D (0.36) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL4983055 | 0.81 | ADRA1D (0.35) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL7510227 | 0.81 | HTR1A (0.46) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL7510228 | 0.81 | HTR1A (0.46) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL4983809 | 0.81 | HTR1A (0.36) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL14188913 | 0.81 | HTR1A (0.38) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL4982169 | 0.81 | ADRA1D (0.41) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL14215920 | 0.79 | ADRA1D (0.40) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL4985067 | 0.79 | ADRA1D (0.38) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A | |
| SCHEMBL14188892 | 0.79 | CA2 (0.39) | TMEM97SIGMAR1ADRA1DHTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | TPH1, HTR1D, HTR1B | TMEM97 3516/4885SIGMAR1 493/4885ADRA1D 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.